Joseph Perez, MD
Allergy · Sugar Land, TXNPI 1750390605
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 364 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AstraZeneca at 24.7% of the total.
Across 364 payments — averaging $22.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Sanofi$1K
- GSK$1K
- Grifols USA, LLC$694
- Regeneron Healthcare Solutions, Inc.$476
- Takeda Pharmaceuticals U.S.A., Inc.$412
- plus $2K from 19 others
Across 44 payments — averaging $294.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$9K
- Alk-abello, Inc$3K
What the payments were for
- Food & beverage$8,05799%
- Education$491%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 64 | $1,999 |
| Sanofi | 50 | $1,178 |
| GSK | 71 | $1,065 |
| Grifols USA, LLC | 38 | $694 |
| Regeneron Healthcare Solutions, Inc. | 22 | $476 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $412 |
| Pfizer | 16 | $364 |
| Kaleo, Inc. | 13 | $228 |
| Boehringer Ingelheim | 11 | $191 |
| Amgen | 4 | $189 |
| Optinose US, Inc. | 11 | $179 |
| Shire North American Group Inc | 4 | $168 |
| GC Biopharma USA, Inc. | 6 | $164 |
| ARS Pharmaceuticals Operations, Inc. | 8 | $152 |
| CSL Behring | 8 | $148 |
| Alk-abello, Inc | 8 | $137 |
| Organon | 3 | $125 |
| Teva Pharmaceuticals USA, Inc. | 2 | $54 |
| Octapharma USA, Inc. | 2 | $53 |
| Hospira, Inc. | 2 | $49 |
| Genentech USA, Inc. | 1 | $28 |
| Aytu Biopharma, Inc. | 1 | $15 |
| Phadia US Inc. | 1 | $15 |
| Novartis | 1 | $15 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,106 in reported general payments places this provider in the 70th percentile of 69 allergy providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HyqviaIgg/Hyaluronidase,recombinant | 13 | $105,787 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 16 | $51,282 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $7,119 |
| Epinephrine | 26 | $6,170 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $3,568 |
| Azelastine Hcl | 51 | $1,660 |
| Fluocinolone AcetonideFluocinolone/Shower Cap | 17 | $680 |
| Carbinoxamine Maleate | 15 | $649 |
| Fluticasone Propionate | 44 | $641 |
| Montelukast Sodium | 48 | $493 |
| Famotidine | 43 | $392 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $363 |
| Levocetirizine Dihydrochloride | 27 | $329 |
| Pantoprazole Sodium | 12 | $77 |
| Azithromycin | 14 | $71 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Hyqvia, Cuvitru | $412 | $157,06929 claims |
| AstraZenecaSymbicort | $1,999 | $7,11918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 69 allergy providers in Texas.
Other allergy in Sugar Land
- Gary GrossDallas$602K
- Rene LeonSouthlake$48K
- Christina HuddlestonDallas$26K
- Alireza ShakouriSouthlake$17K
- Zachary MarshallRoanoke$17K
- Stuart AbramsonSan Angelo$16K
- Patricia DingerSan Antonio$15K
- Brian MillerGeorgetown$15K
- Carlos VitalHouston$14K
- David FuentesBoerne$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.